Andexanet alfa

Andexanet alfa Overview

Andexanet alfa is a specialized, life-saving biological medication utilized in emergency medicine and cardiology. It is a recombinant protein designed specifically to act as an antidote, reversing the blood-thinning effects of certain oral anticoagulants when a patient experiences severe, uncontrolled, or life-threatening bleeding.

What Is Andexanet alfa and How Does It Work

Andexanet alfa acts as a highly specific Targeted Therapy and antidote. Blood thinners like rivaroxaban and apixaban work by inhibiting Factor Xa, a crucial enzyme in the body that helps blood clot. By blocking this enzyme, the drugs prevent dangerous blood clots from forming in conditions like deep vein thrombosis or atrial fibrillation. However, if a patient on these drugs is in a major accident or requires emergency surgery, they can suffer from uncontrollable bleeding.

Andexanet alfa solves this emergency by acting as a “decoy.” It is a genetically modified version of human Factor Xa. When injected into the bloodstream, it actively seeks out the blood-thinning medication (the Factor Xa inhibitors). Because the drug binds to Andexanet alfa with high affinity, it acts like a sponge, pulling the blood thinner away from the patient’s natural Factor Xa.

Once the blood thinner is trapped by the decoy, the patient’s own natural Factor Xa is freed up and can immediately go back to its normal job of forming blood clots and stopping the hemorrhage. Because Andexanet alfa is genetically modified, it cannot form blood clots on its own; it merely acts as a trap for the medication causing the bleeding.

Is Andexanet alfa FDA Approved

Yes, Andexanet alfa was initially approved by the FDA in May 2018. It was developed specifically to address the critical lack of reversal agents for modern direct oral anticoagulants (DOACs).

However, after evaluating required post-marketing clinical trial data (which showed a doubling in blood clot rates and related deaths), the FDA determined its risks outweighed its benefits. In December 2025, AstraZeneca voluntarily withdrew Andexanet alfa from global commercial distribution.

What Is Andexanet alfa Used For

During its period of commercial availability, Andexanet alfa was strictly indicated for adult patients treated with specific Factor Xa inhibitors who required urgent anticoagulation reversal:

• Apixaban (Eliquis) reversal during emergencies.
• Rivaroxaban (Xarelto) reversal during emergencies.
• Specific Scenarios: Only for life-threatening or entirely uncontrolled bleeding events (such as intracranial hemorrhaging or severe gastrointestinal bleeding).

Note: It was never proven effective for, nor indicated to reverse, any other anticoagulants like edoxaban, betrixaban, heparin, or warfarin.

Before Taking Andexanet alfa: Contraindications and Precautions

Because the medication was administered exclusively in life-or-death emergency settings, absolute contraindications were evaluated against the immediate risk of fatal hemorrhage.

Who Should Not Take Andexanet alfa

• There are virtually no absolute contraindications when a patient is facing a fatal hemorrhage. However, extreme caution is used if the patient has a known, severe allergy to the drug or any of its inactive ingredients.
• It should not be used in patients whose bleeding is not life-threatening or can be controlled with standard supportive measures (such as mechanical compression).

Andexanet alfa Pregnancy and Fertility

• Adequate clinical studies of Andexanet alfa in pregnant women were never completed. In emergency settings, it was administered only if the potential benefit justified the potential risk to the fetus.
• It remains unknown whether the drug was excreted in human milk.

Tell Your Doctor Before Taking Andexanet alfa

In the emergency settings where this drug is used, the patient is often unconscious or unable to communicate. If possible, emergency responders or family members must inform the medical team:

• The exact name of the blood thinner the patient takes (e.g., Eliquis or Xarelto).
• The exact time and amount of the last dose of the blood thinner taken.
• Any personal history of blood clots, strokes, or heart attacks.

Andexanet alfa: Dosage and Administration

This medication was restricted strictly to hospital emergency departments and intensive care units under direct critical care supervision

Standard Andexanet alfa Dosage (Historical)

• Dosage was determined based on the specific Factor Xa inhibitor taken, its dose, and the elapsed time since the patient’s last dose:
• Low Dose: An initial IV bolus of 400 mg at a target rate of 30 mg/min, followed by a continuous IV infusion of 4 mg/min for up to 120 minutes.
• High Dose: An initial IV bolus of 800 mg at a target rate of 30 mg/min, followed by a continuous IV infusion of 8 mg/min for up to 120 minutes.

How Andexanet alfa Is Administered

• Supplied as a lyophilized powder that required careful reconstitution with sterile water prior to IV administration.
• Infused directly through a dedicated intravenous line.

Andexanet alfa: Clinical Efficacy and Research

The initial approval was based on data from the ANNEXA-4 trial, which demonstrated that Andexanet alfa rapidly reduced anti-Factor Xa activity and achieved effective hemostasis in a high percentage of patients with acute major bleeding.

However, ongoing safety monitoring and subsequent post-marketing studies revealed a critical safety flaw: removing the protective anticoagulant effect in high-risk cardiovascular patients caused a severe spike in pro-thrombotic activity. The doubled incidence of fatal and non-fatal thrombotic events ultimately led to its withdrawal from global clinical practice.

Andexanet alfa: Side Effects and Safety Profile

The clinical profile of Andexanet alfa was heavily defined by the significant risk of rebound blood clot formation once the anticoagulant was neutralized.

Andexanet alfa Common Adverse Reactions

• Infusion-related physical reactions (flushing, warmth, feeling hot, cough).
• Localized injection site discomfort.
• Pyrexia (fever).

Andexanet alfa Serious Adverse Events

• Ischemic stroke and transient ischemic attack (TIA).
• Acute myocardial infarction (heart attack).
• Deep vein thrombosis (DVT) and pulmonary embolism (PE).
• Sudden cardiac arrest.

Managing Andexanet alfa Side Effects

To manage thrombotic risks, medical teams monitored patients continuously in critical care settings. Guidelines mandated re-instituting anticoagulation therapy as soon as medically feasible once the acute bleeding was controlled.

Andexanet alfa: Interactions and What to Avoid

Primary drug interactions centered on its direct neutralizing action and interference with laboratory assays.

Andexanet alfa Interactions

• Factor Xa Inhibitors: Direct, high-affinity binding to apixaban and rivaroxaban to neutralize their therapeutic effects.
• Heparin: Interference with standard coagulation tests (such as anti-FXa activity assays), causing false readings of heparin monitoring parameters.

Andexanet alfa Food and Alcohol

• Since it was used in life-threatening emergencies, food and alcohol interactions were not applicable to the immediate administration of this drug.

Andexanet alfa: Missed Dose, Overdose and Storage

This medication was not managed by the patient; it was strictly controlled by hospital pharmacies.

Missed Dose of Andexanet alfa

Not applicable, as this was a one-time emergency treatment given by critical care doctors.

Andexanet alfa Overdose and Emergency

An overdose of this antidote would theoretically push the body into a highly pro-coagulant state, massively increasing the risk of widespread, fatal blood clots. The hospital carefully calculated the dose based on specific clinical guidelines to prevent over-administration.

How to Store Andexanet alfa

Unopened vials were stored under refrigeration at 2°C to 8°C (36°F to 46°F) and protected from light. Once reconstituted, the solution had strict, short-term stability limits.

Andexanet alfa: Patient Management and Monitoring

Post-treatment monitoring was the most critical phase of care following the administration of this antidote.

Tests Before Starting Andexanet alfa

• If time permitted during emergency evaluation, the hospital would run baseline coagulation tests and diagnostic imaging (such as CT scans) to locate the exact source and severity of the hemorrhage

Monitoring During Andexanet alfa Treatment

• Continuous monitoring of vital signs, heart rhythm, and oxygen levels.
• Serial imaging (such as repeat head CT scans for brain bleeds) to confirm that the internal bleeding has stopped.
• Intensive monitoring for any signs of new blood clots, such as sudden chest pain, slurred speech, or leg swelling.

Andexanet alfa Do’s and Don’ts

• Patients were advised to wear a medical alert bracelet indicating they took a direct oral anticoagulant (like Eliquis or Xarelto), which alerted emergency medical personnel to prepare appropriate reversal measures during acute accidents.
• Clinical teams understood that restarting anticoagulation as soon as safely possible was essential after the bleeding was controlled, as halting the blood thinner exposed patients to severe underlying risks of stroke and systemic embolism.
• Patients were strictly warned never to stop taking their prescribed blood thinners independently out of fear of bleeding, as unmonitored cessation significantly increased the risk of fatal cardiovascular events.

Frequently Asked Questions

References

• FDA Drugs@FDA Database: Andexxa (Andexanet alfa) Prescribing Information
• DrugBank Online: Andexanet alfa Pharmacological Profile (DB14562)
• Portola Pharmaceuticals Clinical Trial Data (ANNEXA-4 Study)

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider at Liv Hospital or your local clinic before starting or stopping any medication.